Hypertension (high blood pressure) decisions — 2025

The Board denied service connection for chronic urinary tract infections, diabetes mellitus, benign prostatic hypertrophy, hyperparathyroidism and hypercalcemia, hypertension, and special monthly compensation based on aid and attendance/housebound status.

The Board denied the appellant's claim for direct payment of attorney fees from past due benefits awarded in an August 2023 rating decision granting service connection for Parkinson's disease and related symptoms.

The Board remands the claim for service connection for hypertension to obtain an addendum opinion regarding whether the Veteran's major depressive disorder at least as likely as caused or aggravated her obesity, which is a risk factor for hypertension.

The Board granted service connection for coronary artery disease, hypertension, and prostate cancer based on the Veteran's exposure to herbicide agents during his service near the Korean Demilitarized Zone.

The Board granted service connection for hypertension due to exposure to herbicide agents, effective from the date of claim. The appeal for chronic kidney disease was remanded for further evidence.

The Board granted service connection for hypertension, diabetes mellitus type II, and coronary atherosclerosis due to in-service exposure to Agent Orange. Hypomagnesemia was denied as it is not considered a disability for VA compensation purposes.

The Board granted a 50 percent initial evaluation for persistent depressive disorder with anxious distress, but denied increased ratings for hypertension, sleep apnea, and tinnitus.

The Board denied service connection for prostate cancer and remanded the claims for hypertension, ED, and SMC based on loss of use.

The Board is remanding the claim for service connection for hypertension to obtain a medical opinion regarding its etiology.

The Board granted service connection for neuropathy of the bilateral upper and lower extremities, hypertension, aortic aneurysm and aortic regurgitation as secondary to hypertension, and prostate cancer with associated erectile dysfunction. The claims for diabetes mellitus, type II, obstructive sleep apnea, an immune disorder, and a liver disability were remanded.

The Board remands the claims for service connection for hypertension, obstructive sleep apnea, anxiety disorder, and depressive disorder as secondary to service-connected hearing loss and/or tinnitus due to missing evidence.

The Board remands the claims for service connection for hypertension, a heart disability, and an acquired psychiatric disorder to obtain additional medical opinions.

The Board granted service connection for hypertension based on a presumption of chronicity and continuity of relevant symptomatology, as the evidence is at least in equipoise.

The Board denied service connection for malignant melanoma, bilateral hearing loss, and urinary tract condition. It granted an initial 10 percent evaluation for hypertension associated with herbicide exposure.

The Board denied service connection for vitamin D deficiency and hypertension, finding no association between the conditions and military service or exposure to contaminated water at Camp Lejeune.

The Board granted service connection for emphysema and sarcoidosis, assigned an earlier effective date of August 10, 2022 for allergic rhinitis, and granted a higher initial rating of 10 percent for hypertension.

The Board granted an initial increased 10 percent rating for the Veteran's service-connected hypertension based on systolic pressure predominantly 160 or more.

The Board remands the claim for service connection for hypertension to correct a duty to assist error, including obtaining additional service records and an updated medical opinion.

The Board dismissed the claim for entitlement to TDIU since August 11, 2022, as moot due to a combined evaluation of 100 percent. The remaining issues are remanded for further development.

The Board granted an effective date of August 10, 2022, for the grant of service connection for hypertension and a 10 percent evaluation from that date. The TDIU was denied before April 4, 2024.